171 related articles for article (PubMed ID: 19701681)
1. Clinical significance of basal-like subtype in triple-negative breast cancer.
Yamamoto Y; Ibusuki M; Nakano M; Kawasoe T; Hiki R; Iwase H
Breast Cancer; 2009; 16(4):260-7. PubMed ID: 19701681
[TBL] [Abstract][Full Text] [Related]
2. Loss of stromal caveolin-1 expression predicts poor clinical outcome in triple negative and basal-like breast cancers.
Witkiewicz AK; Dasgupta A; Sammons S; Er O; Potoczek MB; Guiles F; Sotgia F; Brody JR; Mitchell EP; Lisanti MP
Cancer Biol Ther; 2010 Jul; 10(2):135-43. PubMed ID: 20431349
[TBL] [Abstract][Full Text] [Related]
3. Human basal-like breast cancer is represented by one of the two mammary tumor subtypes in dogs.
Watson J; Wang T; Ho KL; Feng Y; Mahawan T; Dobbin KK; Zhao S
Breast Cancer Res; 2023 Oct; 25(1):114. PubMed ID: 37789381
[TBL] [Abstract][Full Text] [Related]
4. Biology, metastatic patterns, and treatment of patients with triple-negative breast cancer.
Anders CK; Carey LA
Clin Breast Cancer; 2009 Jun; 9 Suppl 2(Suppl 2):S73-81. PubMed ID: 19596646
[TBL] [Abstract][Full Text] [Related]
5. The Clinicopathological Significance of Basal Markers in Early-Stage Invasive Carcinoma of No Special Type of the Breast.
Dirilenoglu F; Etit DA; Taskaynatan H; Elmali F
Turk Patoloji Derg; 2020; 36(3):195-204. PubMed ID: 32364614
[TBL] [Abstract][Full Text] [Related]
6. Prognostic Markers in Tyrosine Kinases Specific to Basal-like 2 Subtype of Triple-Negative Breast Cancer.
Limsakul P; Choochuen P; Jungrungrueang T; Charupanit K
Int J Mol Sci; 2024 Jan; 25(3):. PubMed ID: 38338684
[TBL] [Abstract][Full Text] [Related]
7. The Landscape of Immune Microenvironments in Racially Diverse Breast Cancer Patients.
Hamilton AM; Hurson AN; Olsson LT; Walens A; Nsonwu-Farley J; Kirk EL; Abdou Y; Downs-Canner SM; Serody JS; Perou CM; Calhoun BC; Troester MA; Hoadley KA
Cancer Epidemiol Biomarkers Prev; 2022 Jul; 31(7):1341-1350. PubMed ID: 35437570
[TBL] [Abstract][Full Text] [Related]
8. Human basal-like breast cancer is represented by one of the two mammary tumor subtypes in dogs.
Watson J; Wang T; Ho KL; Feng Y; Dobbin KK; Zhao S
bioRxiv; 2023 Mar; ():. PubMed ID: 37034591
[TBL] [Abstract][Full Text] [Related]
9. Clinicopathological and epidemiological significance of breast cancer subtype reclassification based on p53 immunohistochemical expression.
Abubakar M; Guo C; Koka H; Sung H; Shao N; Guida J; Deng J; Li M; Hu N; Zhou B; Lu N; Yang XR
NPJ Breast Cancer; 2019; 5():20. PubMed ID: 31372496
[No Abstract] [Full Text] [Related]
10. Breast cryoablation for the palliative treatment of indolent subtype of multicentric triple-negative breast cancer.
Huang ML; Lane DL; Bomar H; Kuerer H
BMJ Case Rep; 2024 Apr; 17(4):. PubMed ID: 38627044
[TBL] [Abstract][Full Text] [Related]
11. Interleukin-3 production by basal-like breast cancer cells is associated with poor prognosis.
Thompson EJ; Escarbe S; Tvorogov D; Farshid G; Gregory PA; Khew-Goodall Y; Madden S; Ingman WV; Lindeman GJ; Lim E; Lopez AF; Bonder CS
Growth Factors; 2024 Feb; ():1-13. PubMed ID: 38299881
[TBL] [Abstract][Full Text] [Related]
12. Triple-negative breast cancer: new perspectives for targeted therapies.
Tomao F; Papa A; Zaccarelli E; Rossi L; Caruso D; Minozzi M; Vici P; Frati L; Tomao S
Onco Targets Ther; 2015; 8():177-93. PubMed ID: 25653541
[TBL] [Abstract][Full Text] [Related]
13. Integrity and Quantity Evaluation of Plasma Cell-Free DNA in Triple Negative Breast Cancer.
Salimi M; Sedaghati Burkhani S
Avicenna J Med Biotechnol; 2019; 11(4):334-338. PubMed ID: 31908742
[TBL] [Abstract][Full Text] [Related]
14. Clinical Significance of Elevated S100A8 Expression in Breast Cancer Patients.
Wang D; Liu G; Wu B; Chen L; Zeng L; Pan Y
Front Oncol; 2018; 8():496. PubMed ID: 30456203
[TBL] [Abstract][Full Text] [Related]
15. Circulating neutrophils from patients with early breast cancer have distinct subtype-dependent phenotypes.
Ramessur A; Ambasager B; Valle Aramburu I; Peakman F; Gleason K; Lehmann C; Papayannopoulos V; Coombes RC; Malanchi I
Breast Cancer Res; 2023 Oct; 25(1):125. PubMed ID: 37858168
[TBL] [Abstract][Full Text] [Related]
16. Prognostic Role of Prolactin-Induced Protein (PIP) in Breast Cancer.
Sauer N; Matkowski I; Bodalska G; Murawski M; Dzięgiel P; Calik J
Cells; 2023 Sep; 12(18):. PubMed ID: 37759471
[TBL] [Abstract][Full Text] [Related]
17. A biologically "old" breast cancer subtype in a very young woman: a plea of ignorance.
Sniadecki M; Krajewska M; Stasiak M; Walkiewicz A; Guzik PW
Ginekol Pol; 2023; 94(12):1032-1033. PubMed ID: 37417379
[No Abstract] [Full Text] [Related]
18. Erratum to: Clinical significance of Notch receptors in triple negative breast cancer.
Shah H; Mistry M; Patel N; Vora H
Breast Dis; 2024; 43(1):159. PubMed ID: 38820045
[No Abstract] [Full Text] [Related]
19. Correction: Halting ErbB-2 isoforms retrograde transport to the nucleus as a new theragnostic approach for triple-negative breast cancer.
Madera S; Izzo F; Chervo MF; Dupont A; Chiauzzi VA; Bruni S; Petrillo E; Merin SS; De Martino M; Montero D; Levit C; Lebersztein G; Anfuso F; Roldán Deamicis A; Mercogliano MF; Proietti CJ; Schillaci R; Elizalde PV; Cordo Russo RI
Cell Death Dis; 2023 Dec; 14(12):833. PubMed ID: 38102106
[No Abstract] [Full Text] [Related]
20. Tackling the Biological Diversity in Early Triple-Negative Breast Cancer.
Oliveira M; Saura C
Breast Care (Basel); 2020 Jun; 15(3):205-207. PubMed ID: 32774213
[No Abstract] [Full Text] [Related]
[Next] [New Search]
